Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(7%)
Results Posted
20%(2 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
3
21%
Ph phase_4
2
14%
Ph phase_1
9
64%

Phase Distribution

9

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
9(64.3%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 4Post-market surveillance
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(1)

Detailed Status

Completed10
Active, not recruiting1
Terminated1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (64.3%)
Phase 23 (21.4%)
Phase 42 (14.3%)

Trials by Status

active_not_recruiting17%
completed1071%
terminated17%
withdrawn17%
unknown17%

Recent Activity

1 active trials
Showing 5 of 14
active_not_recruitingphase_2

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
withdrawnphase_1

Lucentis for New Onset Neovascular Glaucoma

NCT00727038
completedphase_1

Pilot Study of X-82 in Patients With Wet AMD

NCT01674569
completedphase_4

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

NCT03409250
terminatedphase_4

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

NCT00423189
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04704921Phase 2

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Active Not Recruiting
NCT00727038Phase 1

Lucentis for New Onset Neovascular Glaucoma

Withdrawn
NCT01674569Phase 1

Pilot Study of X-82 in Patients With Wet AMD

Completed
NCT03409250Phase 4

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Completed
NCT00423189Phase 4

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Terminated
NCT00403039Phase 1

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

Completed
NCT00570726Phase 1

Treatment of Failing Blebs With Ranibizumab

Completed
NCT00387582Phase 2

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Completed
NCT01028248Phase 1

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

Completed
NCT00406471Phase 1

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

Completed
NCT00570193Phase 1

Photodynamic and Pharmacologic Treatment of CNV

Completed
NCT00373659Phase 2

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Completed
NCT01011374Phase 1

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Unknown
NCT00395707Phase 1

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14